Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Mitsubishi Tanabe Pharma Corp    4508   JP3469000008

MITSUBISHI TANABE PHARMA CORP

(4508)
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Researchers from Mitsubishi Tanabe Pharma America Inc. Report Recent Findings in Organic Chemistry (Ligand-Dependent Site-Selective Suzuki Cross-Coupling of 4-Bromopyrazol-5-yl Triflates): Chemistry - Organic Chemistry

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 05:55pm EDT

2019 AUG 14 (NewsRx) -- By a News Reporter-Staff News Editor at Daily Asia Business -- Current study results on Chemistry - Organic Chemistry have been published. According to news reporting out of Saitama, Japan, by NewsRx editors, research stated, “Ligand-dependent Suzuki cross-coupling of 4-bromopyrazol-5-yl triflates has been developed. This approach enabled selective introduction of an aryl substituent at the C4 or C5 position in pyrazoles.”

Our news journalists obtained a quote from the research from Mitsubishi Tanabe Pharma America Inc., “This protocol is the first example in which the cross-coupling proceeded predominantly at the C4 position in pyrazoles, which is generally recognized as the least reactive position. The selection of phosphine ligands switched the order of arylation.”

According to the news editors, the research concluded: “This method should be highly useful for preparing diverse poly-substituted pyrazole derivatives.”

For more information on this research see: Ligand-Dependent Site-Selective Suzuki Cross-Coupling of 4-Bromopyrazol-5-yl Triflates. The Journal of Organic Chemistry, 2019;():. The Journal of Organic Chemistry can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA.

Our news journalists report that additional information may be obtained by contacting R. Sakakibara, Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda, Saitama 335-8505, Japan. Additional authors for this research include K. Itoh and H. Fujii.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1021/acs.joc.9b01306. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the The Journal of Organic Chemistry is: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Copyright © 2019 NewsRx LLC, Daily Asia Business, source Geographic Newsletters

Stocks mentioned in the article
ChangeLast1st jan.
MITSUBISHI CHEMICAL HOLDINGS CORP. 1.40% 730 End-of-day quote.-10.10%
MITSUBISHI TANABE PHARMA CORP 0.86% 1167 End-of-day quote.-24.37%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MITSUBISHI TANABE PHARMA C
08/12Influenza Vaccines Market is Expected to Surpass USD 6 billion by 2025 | Key ..
AQ
04/26Salix Enters Into Exclusive License Agreement with Mitsubishi Tanabe Pharma t..
AQ
04/16ExpreS2ion Biotechnologies Announces Research License Agreement with Mitsubis..
AQ
04/06AnGes Obtains Conditional Approval in Japan for HGF Gene Therapy to Treat Cri..
AQ
03/27MITSUBISHI TANABE PHARMA CORP : Ex-dividend day for final dividend
FA
03/20Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results an..
AQ
01/30MITSUBISHI TANABE PHARMA CORP : quaterly earnings release
01/14MITSUBISHI TANABE PHARMA : other Japanese firms visit Israel to strengthen busin..
AQ
2018MITSUBISHI TANABE PHARMA : "Materiality" posted
PU
2018MITSUBISHI TANABE PHARMA : Announcement of FY2018 2nd Quarter Financial Results ..
PU
More news
Financials (JPY)
Sales 2020 392 B
EBIT 2020 13 171 M
Net income 2020 5 950 M
Finance 2020 341 B
Yield 2020 4,80%
P/E ratio 2020 87,2x
P/E ratio 2021 42,2x
EV / Sales2020 0,82x
EV / Sales2021 0,81x
Capitalization 661 B
Chart MITSUBISHI TANABE PHARMA CORP
Duration : Period :
Mitsubishi Tanabe Pharma Corp Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MITSUBISHI TANABE PHARMA C
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 1 291,11  JPY
Last Close Price 1 167,00  JPY
Spread / Highest target 62,8%
Spread / Average Target 10,6%
Spread / Lowest Target -14,3%
EPS Revisions
Managers
NameTitle
Masayuki Mitsuka President & Representative Director
Eizou Tabaru Director, Head-Finance & Accounting
Yoshiaki Ishizaki Director & Managing Executive Officer
Seiichi Murakami Director & Managing Executive Officer
Takashi Kobayashi Representative Director & Chief Compliance Officer
Sector and Competitors
1st jan.Capitalization (M$)
MITSUBISHI TANABE PHARMA CORP-24.37%6 142
JOHNSON & JOHNSON2.48%349 030
ROCHE HOLDING LTD.12.24%239 457
ROCHE HOLDING13.20%239 457
MERCK AND COMPANY12.80%220 679
NOVARTIS17.81%205 341